Vol 6, No 2 (2020)
Review paper
Published online: 2020-09-04
Choroba Kawasaki — czy zbliżamy się do poznania etiologii?
DOI: 10.5603/FR.2020.0010
Forum Reumatol 2020;6(2):80-84.
Abstract
Choroba Kawasaki to układowe zapalenie średnich i małych naczyń o samoograniczającym się przebiegu, występujące najczęściej u dzieci do 5. roku życia. Z uwagi na znaczną predylekcję do zajmowania tętnic wieńcowych, choroba Kawasaki
jest najczęstszą przyczyną nabytych wad serca w populacji pediatrycznej w krajach rozwiniętych. Wystąpienie objawów choroby i jej przebieg wydaje się wynikiem zaburzeń układu immunologicznego, skutkujących (poprzez stymulację cytokin prozapalnych: interleukiny 6, 8 i 17, czynnika martwicy nowotworów α, interferonu γ i hamowanie przeciwzapalnych: interleukiny 10, transformującego czynnika wzrostu β) nadmierną reakcją na nieznany antygen u osób predysponowanych genetycznie (posiadających m.in. geny kodujące: kinazę inozytolo-1,4,5-trifosforanową, kaspazę-3, kinazę tyrozynową limfocytów B, HLA DQB2, HLA DOB oraz ligand CD 40).
Keywords: choroba Kawasakietiopatogenezapredyspozycja genetycznaimmunologia
References
- Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child. 2015; 100(11): 1084–1088.
- Kawasaki T. Acute febrile muco-cutaneous lymph node syndrome in young children with unique digital desquamation. Jpn J Allergol. 1967; 16:178-222 (japoński.
- Dietz SM, van Stijn D, Burgner D, et al. Dissecting Kawasaki disease: a state-of-the-art review. Eur J Pediatr. 2017; 176(8): 995–1009.
- Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol. 2012; 22(2): 79–85.
- McCrindle BW, Rowley AH, Newburger JW, et al. American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017; 135(17): e927–e999.
- Dimitriades VR, Brown AG, Gedalia A. Kawasaki disease: pathophysiology, clinical manifestations, and management. Curr Rheumatol Rep. 2014; 16(6): 423.
- Bayers S, Shulman ST, Paller AS. Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis. J Am Acad Dermatol. 2013; 69(4): 501.e1–11; quiz 511.
- Holman RC, Belay ED, Christensen KY, et al. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010; 29(6): 483–488.
- Fraison JB, Sève P, Dauphin C, et al. CRI and the French Vasculitis Study Group. Kawasaki disease in adults: Observations in France and literature review. Autoimmun Rev. 2016; 15(3): 242–249.
- Lynch M, Holman RC, Mulligan A, et al. Kawasaki syndrome hospitalizations in Ireland, 1996 trough 2000. Pediatr Infect Dis J. 2003; 22: 959–963.
- Harnden A, Mayon-White R, Perera R, et al. Kawasaki disease in England: ethnicity, deprivation, and respiratory pathogens. Pediatr Infect Dis J. 2009; 28(1): 21–24.
- Schiller B, Fasth A, Björkhem G, et al. Kawasaki disease in Sweden: incidence and clinical features. Acta Paediatr. 1995; 84(7): 769–774.
- Fischer TK, Holman RC, Yorita KL, et al. Kawaski syndrome in Denmark. Pediatr Infect Dis J. 2007; 26: 411–415.
- Takahashi K, Oharaseki T, Yokouchi Y. Update on etio and immunopathogenesis of Kawasaki disease. Curr Opin Rheumatol. 2014; 26(1): 31–36.
- Makino N, Nakamura Y, Yashiro M, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015; 25(3): 239–245.
- Agarwal S, Agrawal DK. Kawasaki disease: etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol. 2017; 13(3): 247–258.
- Bhagavan NV. Regulation of Gene Expression. Medical Biochemistry. Academic Press, San Diego 2002: 609.
- Onouchi Y, Ozaki K, Buns JC, et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet. 2010; 19(14): 2898–2906.
- Kim KY, Kim DS. Recent Advances in Kawasaki Disease. Yonsei Med J. 2016; 57(1): 15–21.
- Onouchi Y, Ozaki K, Burns JC, et al. Japan Kawasaki Disease Genome Consortium, US Kawasaki Disease Genetics Consortium. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012; 44(5): 517–521.
- Yoon KL. Update of genetic susceptibility in patients with Kawasaki disease. Korean J Pediatr. 2015; 58(3): 84–88.
- Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008; 40(1): 35–42.
- Wang CL, Wu YT, Liu CA, et al. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to coronary artery lession and disease progres in Kawasaki disease. Pediatrics. 2003; 111: 140–147.
- Onouchi Y, Onoue S, Tamari M, et al. CD40 ligand gene and Kawasaki disease. Eur J Hum Genet. 2004; 12(12): 1062–1068.
- Usta Guc B, Cengiz N, Yildirim SV, et al. Cytomegalovirus infection in a patient with atypical Kawasaki disease. Rheumatol Int. 2008; 28(4): 387–389.
- Chang LY, Lu CY, Shao PL, et al. Viral infections associated with Kawasaki disease. J Formos Med Assoc. 2014; 113(3): 148–154.
- Turnier JL, Anderson MS, Heizer HR, et al. Concurrent Respiratory Viruses and Kawasaki Disease. Pediatrics. 2015; 136(3): e609–e614.
- Suenaga T, Suzuki H, Shibuta S, et al. Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J Pediatr. 2009; 155(2): 266–270.
- Matsubara K, Fukaya T, Miwa K, et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin Exp Immunol. 2006; 143(3): 427–434.
- Yeung RSM. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol. 2010; 22(5): 551–560.
- Jiang ZG, Liu L, Yang CY, et al. [Value of anti-neutrophil cytoplasmic antibody in diagnosis of Kawasaki disease]. Zhongguo Dang Dai Er Ke Za Zhi. 2012; 14(1): 45–47.
- Marrani E, Burns JC, Cimaz R. How we should classify Kawasaki diesease? Front Immunol. 2018; 9: 2974.
- Guilpain P, Mouthon L. Antiendothelial cells autoantibodies in vasculitis-associated systemic diseases. Clin Rev Allergy Immunol. 2008; 35(1-2): 59–65.
- Grunebaum E, Blank M, Cohen S, et al. The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies. Clin Exp Immunol. 2002; 130(2): 233–240.
- Makino N, Nakamura Y, Yashiro M, et al. Epidemiological observations of Kawasaki disease in Japan, 2013-2014. Pediatr Int. 2018; 60(6): 581–587.
- Kim GiB, Park S, Eun LY, et al. Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. Pediatr Infect Dis J. 2017; 36(5): 482–485.
- Dos Santos Domingues A, Selleski N, Uenishi RH, et al. The possible link between coeliac and Kawasaki diseases in Brazil: a cross-sectional study. BMJ Open. 2018; 8(2): e018803.
- Cho HK, Eun LY, Song JS, et al. A Case of Vitiligo after Kawasaki's Disease. Ann Dermatol. 2009; 21(1): 75–77.
